Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan (ICKSH 2026) - Mar 11, 2026 - Pres time: Mar 28, 2026; 09:00 AM - 09:20 AM; Location: Galaxy Theater; "For patients with major subtypes of peripheral T -cell lymphoma (PTCL), including PTCL not otherwise specified, angioimmunoblastic T -cell lymphoma (AITL), and anaplastic large cell lymphoma, the 2024 Japanese Society of Hematology (JSH) guidelines recommend the use of brentuximab vedotin (BV) -CHP for CD30 -positive tumors and CHOP -like regimens for CD30 -negative tumors as the first -line treatment...For patients with relapsed /refractory T-cell and NK/T -cell lymphoma, many therapeutic drugs (mogamulizumab, BV , pralatrexate, forodesine, romidepsin, alectinib, denileukin diftitox, tucidinostat, darinaparsin, and valemetostat) are approved and available in Japan...However, among immune checkpoint inhibitors, only atezolizumab was approved for the treatment of ENKL in 2025, and little experience is available with its use. Patients with ENKL in Japan account for less than 1% of all lymphoma patients, which is as low as in Western countries. To fill these gaps,..."
Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin's Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8
|